TNFSF11 and osteomyelitis: Similar to outcomes seen in alendronate-treated mice, osteonecrosis developed in mice administered anti-RANKL antibody, a different anti-resorptive agent (Fig. S2), suggesting that in the presence of osteomyelitis, treatment with any anti-bone resorbing agent promotes osteonecrosis development.